TY - JOUR
T1 - Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?
AU - Zabalza, Ana
AU - Arrambide, Georgina
AU - Otero-Romero, Susana
AU - Pappolla, Agustín
AU - Tagliani, Paula
AU - López-Maza, Samuel
AU - Cárdenas-Robledo, Simón
AU - Esperalba, Juliana
AU - Fernández-Naval, Candela
AU - Martínez-Gallo, Monica
AU - Castillo, Mireia
AU - Bonastre, Mercè
AU - Resina-Salles, Mireia
AU - Bertran, Jordina
AU - Rodriguez-Barranco, Marta
AU - Carbonell-Mirabent, Pere
AU - Gonzalez, Marina
AU - Merchan, Miguel
AU - Quiroga-Varela, Ana
AU - Miguela, Albert
AU - Gómez, Imma
AU - Álvarez, Gary
AU - Robles, René
AU - Perez del Campo, Dúnia
AU - Queralt, Xavier
AU - Soler, Maria José
AU - Agraz, Irene
AU - Martinez-Valle, Fernando
AU - Rodríguez-Acevedo, Breogán
AU - Midaglia, Luciana
AU - Vidal-Jordana, Ángela
AU - Cobo-Calvo, Álvaro
AU - Tur, Carmen
AU - Galan, Ingrid
AU - Castillo, Joaquín
AU - Río, Jordi
AU - Espejo, Carmen
AU - Comabella, Manuel
AU - Nos, Carlos
AU - Sastre-Garriga, Jaume
AU - Ramió-Torrentà, Lluís
AU - Tintoré, Mar
AU - Montalban, Xavier
N1 - Publisher Copyright:
© The Author(s), 2022.
PY - 2022/6
Y1 - 2022/6
N2 - Background: The effect of disease-modifying therapies on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine response is unclear. Objectives: We aim to determine the immunological responses to SARS-CoV-2 in multiple sclerosis (MS) and anti-CD20-treated patients with other autoimmune diseases (AID). Methods: Humoral and cellular responses we determined before and 30-90 days after vaccination in patients with MS and anti-CD20-treated patients with other AID in two Catalan centers. Results: 457 patients were enrolled. Findings showed that humoral response decreased under anti-CD20s or sphingosine 1-phosphate receptor modulators (S1PRM) and with longer treatment duration and increased after 4.5 months from the last anti-CD20 infusion. Cellular response decreased in S1PRM-treated. Patients on anti-CD20 can present cellular responses even in the absence of antibodies. Conclusion: Anti-CD20s and S1PRM modify the immunological responses to SARS-CoV-2 vaccines.
AB - Background: The effect of disease-modifying therapies on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine response is unclear. Objectives: We aim to determine the immunological responses to SARS-CoV-2 in multiple sclerosis (MS) and anti-CD20-treated patients with other autoimmune diseases (AID). Methods: Humoral and cellular responses we determined before and 30-90 days after vaccination in patients with MS and anti-CD20-treated patients with other AID in two Catalan centers. Results: 457 patients were enrolled. Findings showed that humoral response decreased under anti-CD20s or sphingosine 1-phosphate receptor modulators (S1PRM) and with longer treatment duration and increased after 4.5 months from the last anti-CD20 infusion. Cellular response decreased in S1PRM-treated. Patients on anti-CD20 can present cellular responses even in the absence of antibodies. Conclusion: Anti-CD20s and S1PRM modify the immunological responses to SARS-CoV-2 vaccines.
KW - cellular response
KW - COVID-19
KW - disease-modifying therapy
KW - humoral response
KW - multiple sclerosis
KW - SARS-CoV-2
UR - http://www.scopus.com/inward/record.url?scp=85129798248&partnerID=8YFLogxK
U2 - 10.1177/13524585221089540
DO - 10.1177/13524585221089540
M3 - Article
C2 - 35475363
AN - SCOPUS:85129798248
SN - 1352-4585
VL - 28
SP - 1138
EP - 1145
JO - Multiple Sclerosis Journal
JF - Multiple Sclerosis Journal
IS - 7
ER -
